ArticleJournal of immunology (Baltimore, Md. : 1950)2013
A peptide antagonist disrupts NK cell inhibitory synapse formation.
Article in Journal of immunology (Baltimore, Md. : 1950), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Review
- Article
- NK cell education: Physiological and pathological influences.Frontiers in immunology · 2023Review
- Review
- Conserved and variable natural killer cell receptors: diverse approaches to viral infections.Immunology · 2019Review
- Natural selection for killer receptors and their MHC class I ligands: In pursuit of gene pairs that fit well in tandem.Journal of leukocyte biology · 2019Review
- Spatial Clustering of Receptors and Signaling Molecules Regulates NK Cell Response to Peptide Repertoire Changes.Frontiers in immunology · 2019Article
- Natural Killer Cell Education and the Response to Infection and Cancer Therapy: Stay Tuned.Trends in immunology · 2018Review
- Missing or altered self: human NK cell receptors that recognize HLA-C.Immunogenetics · 2017Review
- The Intergenic Recombinant HLA-B∗46:01 Has a Distinctive Peptidome that Includes KIR2DL3 Ligands.Cell reports · 2017Article
- Natural Killer Cell Interactions with Classical and Non-Classical Human Leukocyte Antigen Class I in HIV-1 Infection.Frontiers in immunology · 2017Review
- Peptide-dependent HLA-KIR-mediated regulation of NK cell function.Journal of hepatology · 2016Article
- Peptide selectivity discriminates NK cells from KIR2DL2- and KIR2DL3-positive individuals.European journal of immunology · 2015Article
- MHC and KIR Polymorphisms in Rhesus Macaque SIV Infection.Frontiers in immunology · 2015Review
- Effects of Peptide on NK cell-mediated MHC I recognition.Frontiers in immunology · 2014Review
- Synergistic inhibition of natural killer cells by the nonsignaling molecule CD94.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Immunogenetics of HIV disease.Immunological reviews · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Productive engagement of MHC class I by inhibitory NK cell receptors depends on the peptide bound by the MHC class I molecule. Peptide:MHC complexes that bind weakly to killer cell Ig-like receptors (KIRs) can antagonize the inhibition mediated by high-affinity peptide:MHC complexes and cause NK cell activation. We show that low-affinity peptide:MHC complexes stall inhibitory signaling at the step of Src homology protein tyrosine phosphatase 1 recruitment and do not go on to form the KIR microclusters induced by high-affinity peptide:MHC, which are associated with Vav dephosphorylation and downstream signaling. Furthermore, the low-affinity peptide:MHC complexes prevented the formation of KIR microclusters by high-affinity peptide:MHC. Thus, peptide antagonism of NK cells is an active phenomenon of inhibitory synapse disruption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.